Literature DB >> 709563

Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP) treatment of non-oat cell bronchogenic carcinoma.

N J Vogelzang, P D Bonomi, A H Rossof, J Wolter.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 709563

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  6 in total

Review 1.  Combination chemotherapy for advanced adenocarcinoma of the lung. A review.

Authors:  J B Sørensen; H H Hansen
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 2.  Chemotherapy of advanced non-small cell lung cancer. A review.

Authors:  B J Takasugi; T P Miller
Journal:  Invest New Drugs       Date:  1984       Impact factor: 3.850

3.  Renal impairment following the combined use of high-dose methotrexate and procarbazine.

Authors:  P Price; H Thompson; E M Bessell; H J Bloom
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

4.  Comparison of survival in nonresected well differentiated and poorly differentiated adenocarcinoma of the lung.

Authors:  N Saijo; H Niitani; K Tominaga; K Eguchi; H Koketsu; T Fujino; S Ishikawa
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

Review 5.  Current options in the treatment of non-small cell lung cancer.

Authors:  D Faulds
Journal:  Drugs       Date:  1992       Impact factor: 9.546

6.  Combination chemotherapy (high-dose methotrexate with citrovorum factor rescue, mechlorethamine, and procarbazine) in non-small cell lung cancer.

Authors:  R R Bhasin; C P Nogeirie
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.